Drug Trial Radar · NCT05249426
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Apr 12, 2022
Primary completion
Jul 15, 2024
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether combining different medicines make tumours shrink. The tested medicines in this study are antibodies that act in different ways against cancer. BI 765063 and ezabenlimab may help the immune system fight cancer (checkpoint inhibitors). Cetuximab blocks growth signals and may prevent the tumour from growing. BI 836880 blocks the formation of new blood vessels that the tumour needs to grow. With amendments of the protocol, all participants receive cetuximab in addition to BI 765063 and ezabenlimab. Ezabenlimab treatment and any other assigned treatment are given no longer than 2 years. Previously, BI 765063 and ezabenlimab were also given alone, or in combination with chemotherapy, or with BI 836880. BI 765063, ezabenlimab, and BI 836880 are given as infusions into veins every 3 weeks. Cetuximab is given as an infusion every 1 or 2 weeks. Participants can stay in the study as long as they benefit from treatment and can tolerate it. They regularly visit the study site where doctors check participants' health and take note of any unwanted effects. The doctors also monitor the size of the tumour.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
BI 765063Drug
BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
EzabenlimabDrug
Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
BI 836880Drug
BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
CetuximabDrug
Cetuximab
Investigator´s Choice ChemotherapyOther
Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR)Time frame: Up to 24 months.
Locations
25 sites in 11 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California
CTR Georges-François Leclerc
Dijon, France
CTR Leon Berard
Lyon, France
HOP Timone
Marseille, France
INS Curie
Paris, France
HOP Civil
Strasbourg, France
INS Claudius Regaud IUCT-Oncopole
Toulouse, France
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, Japan
Hospital Sultan Ismail
Johor Bahru, Malaysia
Sarawak General Hospital
Kuching, Sarawak, Malaysia
ARKE SMO S.A. de C.V
Mexico City, Mexico
FAICIC S de RL de C.V.
Veracruz, Mexico
Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V.
Zapopan, Mexico
ARENSIA Exploratory Medicine
Chisinau, Moldova
Mandziuk Slawomir Specialist Medical Practice
Lublin, Poland
"Prof. Dr. Alexandru Trestioreanu" Oncology Institut
Bucharest, Romania
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Cluj-Napoca, Romania
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
Hospital Clínico San Carlos
Madrid, Spain
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Songklanagarind Hospital
Songkhla, Thailand
King's College Hospital
London, United Kingdom
The Royal Marsden Hospital, Chelsea
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.